The GE Healthcare (Chalfont St. Giles, United Kingdom) BiaCore T200 system is the successor to the popular T100 instrument.

GE Healthcare's Biacore systems enable the measurement and characterization of almost any type of biomolecular interaction without the need for labels, providing high-quality data on binding affinity, kinetics and specificity, as well as concentration measurements based on specific binding activity. Real-time, label-free detection of interactions is provided by surface plasmon resonance (SPR), which measures changes in mass concentration close to a sensor surface.

Biacore systems are used in areas such as pharmaceutical drug discovery, antibody characterization, immunogenicity, drug development, and manufacture, and throughout life science research. Key applications include quantification of binding affinity and kinetics, determination of binding specificity and number of binding sites, characterization of mechanism of action, confirmation of biomolecule binding to target, screening of fragment libraries, and characterization of immune responses.

The new T200 system expands the range of kinetic parameters that can be studied with the highest precision and confidence, from the fastest on-rates to the slowest off-rates. Guided workflows and the ability to analyze up to 384 samples in unattended runs facilitate rapid data acquisition for a large range of biomolecular interaction studies. Calibration-free concentration analysis enables highly reproducible, precise measurement of active protein concentration, whether or not a standard is available.

Biacore T200 software also provides dedicated support for immunogenicity testing as well as for detection and characterization of anti-drug antibodies during preclinical and clinical development.

Related Links:
GE Healthcare